Executives from CVS Health and Aetna sought to assure lawmakers that their US$69 billion merger would create value for consumers and not result in anti-competitive behavior. They spoke at a hearing before the House Judiciary Regulatory Reform, Commercial and Antitrust Law Subcommittee on Tuesday, February 27.
At the hearing, a CVS official told a House subcommittee that the proposed merger of pharmacy giant and pharmacy benefit manager CVS with health insurer Aetna could actually bring more business to some primary care providers.
Despite raising concerns that the deal would be bad for consumers and the healthcare system, the AMA’s statement did not ask Congress or regulators to block the deal.
Full Content: Medpage Today
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Passes ‘Take It Down Act,’ the First Major AI-Related Federal Regulation
Apr 29, 2025 by
CPI
Michigan Sues Express Scripts, Prime Therapeutics for Alleged Price-Fixing Scheme
Apr 29, 2025 by
CPI
Tech Rivals Testify as FTC Antitrust Trial Against Meta Enters Defining Phase
Apr 29, 2025 by
CPI
Spanish Judge Investigates Nationwide Blackout as Possible Cyber Threat
Apr 29, 2025 by
CPI
Trump Administration Pushes EU to Delay AI Regulations
Apr 29, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece